文献速递神经免疫

利妥昔单抗治疗视神经脊髓炎谱系疾病的安全性与有效性:RIN-1多中心随机双盲安慰剂对照试验

Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial.
PubMed 文献 · Lancet Neurol · 2020-03-18

这项在日本8家医院开展的多中心随机双盲安慰剂对照试验,纳入38例AQP4抗体阳性且正在口服5-30 mg/日类固醇的NMOSD患者,评估利妥昔单抗预防复发的安全性和有效性。

要点

  • 利妥昔单抗组72周内无复发,安慰剂组7例(37%)复发。
  • 严重不良事件两组各4例,所有患者均恢复,无死亡报告。

核心结论

  • 利妥昔单抗可在72周内预防AQP4抗体阳性NMOSD患者的复发。
  • 利妥昔单抗可能作为AQP4抗体阳性NMOSD患者的有效维持治疗。

研究设计与样本

  • 多中心、随机、双盲、安慰剂对照临床试验,在日本8家医院开展。
  • 按1:1随机分配至利妥昔单抗组(n=19)或安慰剂组(n=19),以类固醇剂量和既往2年复发次数为分层因素。
  • 利妥昔单抗375 mg/m2静脉给药,每周1次共4周,随后在第24周和第48周各予1000 mg(每2周1次)。
  • 主要结局为72周内首次复发时间,主要分析采用意向性治疗原则,安全性分析纳入至少接受1次输注的患者。

主要发现

  • 利妥昔单抗组3例(16%)中止研究并按删失处理。
  • 严重不良事件共8例:利妥昔单抗组3例(16%)发生4例事件(腰椎压缩性骨折和右足趾甲周感染、复视、子宫癌),安慰剂组2例(11%)发生4例事件(青光眼加重和右眼术后前房出血、视力损害和无症状脑白质MRI病灶)。
  • 所有患者均恢复,无死亡报告。

临床怎么用

  • 对于AQP4抗体阳性且病情活动较轻的NMOSD患者,利妥昔单抗可作为维持治疗以预防复发。
  • 治疗期间需监测严重不良事件,包括感染、骨折和肿瘤等。

局限性

  • 样本量小(共38例)。
  • 纳入的患者病情活动较轻。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pharmacological prevention against relapses in patients with neuromyelitis optica spectrum disorder (NMOSD) is developing rapidly. We aimed to investigate the safety and efficacy of rituximab, an anti-CD20 monoclonal antibody, against relapses in patients with NMOSD. METHODS: We did a multicentre, randomised, double-blind, placebo-controlled clinical trial at eight hospitals in Japan. Patients aged 16-80 years with NMOSD who were seropositive for aquaporin 4 (AQP4) antibody, were taking 5-30 mg/day oral steroids, and had an Expanded Disability Status Scale (EDSS) score of 7·0 or less were eligible for the study. Individuals taking any other immunosuppressants were excluded. Participants were randomly allocated (1:1) either rituximab or placebo by a computer-aided dynamic random allocation system. The doses of concomitant steroid (converted to equivalent doses of prednisolone) and relapses in previous 2 years were set as stratification factors. Participants and those assessing outcomes were unaware of group assignments. Rituximab (375 mg/m2) was administered intravenously every week for 4 weeks, then 6-month interval dosing was done (1000 mg every 2 weeks, at 24 weeks and 48 weeks after randomisation). A matching placebo was administered intravenously. Concomitant oral prednisolone was gradually reduced to 2-5 mg/day, according to the protocol. The primary outcome was time to first relapse within 72 weeks. Relapses were defined as patient-reported symptoms or any new signs consistent with CNS lesions and attributable objective changes in MRI or visual evoked potential. The primary analysis was done in the full analysis set (all randomly assigned patients) and safety analyses were done in the safety analysis set (all patients who received at least one infusion of assigned treatment). The primary analysis was by intention-to-treat principles. This trial is registered with the UMIN clinical trial registry, UMIN000013453. FINDINGS: Between May 10, 2014, and Aug 15, 2017, 38 participants were recruited and randomly allocated either rituximab (n=19) or placebo (n=19). Three (16%) patients assigned rituximab discontinued the study and were analysed as censored cases. Seven (37%) relapses occurred in patients allocated placebo and none were recorded in patients assigned rituximab (group difference 36·8%, 95% CI 12·3-65·5; log-rank p=0·0058). Eight serious adverse events were recorded, four events in three (16%) patients assigned rituximab (lumbar compression fracture and infection around nail of right foot [n=1], diplopia [n=1], and uterine cancer [n=1]) and four events in two (11%) people allocated to placebo (exacerbation of glaucoma and bleeding in the right eye chamber after surgery [n=1], and visual impairment and asymptomatic white matter brain lesion on MRI [n=1]); all patients recovered. No deaths were reported. INTERPRETATION: Rituximab prevented relapses for 72 weeks in patients with NMOSD who were AQP4 antibody-positive. This study is limited by its small sample size and inclusion of participants with mild disease activity. However, our results suggest that rituximab could be useful maintenance therapy for individuals with NMOSD who are AQP4 antibody-positive. FUNDING: Japanese Ministry of Health, Labour and Welfare, Japan Agency for Medical Research and Development, and Zenyaku Kogyo.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Tahara M, Oeda T, Okada K, et al. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2020. PMID: 32199095. doi:10.1016/S1474-4422(20)30066-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。